Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion type Assertion NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_head.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion description "[The genetic polymorphism affecting TPMT activity displays an important inter-subject variability in metabolites pharmacokinetics and influences the balance between 6-MP efficacy and toxicity: patients with high 6-TGN levels are at risk of myelosuppression while patients with high levels of methylated derivates are at hepatotoxic risk.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_provenance.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion evidence source_evidence_literature NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_provenance.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion SIO_000772 22421815 NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_provenance.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion wasDerivedFrom befree-20150227 NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_provenance.
- NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_assertion wasGeneratedBy ECO_0000203 NP730996.RAbaRAHg6r0xu1a9uc2Ma4vdsdn-uf-yJUzoLgNOikMf0130_provenance.